Cargando…
Botulinum Toxin Type A for Cephalic Cutaneous Allodynia in Chronic Migraine: A Randomized, Double-Blinded, Placebo-Controlled Trial
Cephalic allodynia (CA) can be observed in 50-70% of patients with chronic migraine (CM). The aim of this trial was to assess the efficacy of botulinum toxin type A (Botx-A) in the treatment of CA associated with CM. In this placebo-controlled trial, patients were randomized either into Botx-A or 0....
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
PAGEPress Publications, Pavia, Italy
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274405/ https://www.ncbi.nlm.nih.gov/pubmed/25568735 http://dx.doi.org/10.4081/ni.2014.5133 |